Skip to main content

BRIEF-Janssen Says Darzalex Combination Regimen Shows Improved Outcomes

* JANSSEN - DARZALEX (DARATUMUMAB) COMBINATION REGIMEN SIGNIFICANTLY IMPROVED OUTCOMES FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS TRANSPLANT INELIGIBLE Source text for Eikon: Further company coverage:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.